Evidence map›Paper›PMID 25710962›Full record

ArticleJournal of the National Cancer Institute2015

Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Eleanor I Ager, Sergey V Kozin, Nathaniel D Kirkpatrick, Giorgio Seano, David P Kodack, Vasileios Askoxylakis, Yuhui Huang, Shom Goel, Matija Snuderl, Alona Muzikansky and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.

  1. Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Pooled it
  2. Article
  3. Review
  4. Matrix Metalloproteinase 14 in Corneal Neovascularization.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  13. Review
  14. Article
  15. Substrate derived sequences act as subsite-blocking motifs in protease inhibitory antibodies.Protein science : a publication of the Protein Society · 2023
    Article
  16. Macrophages in immunoregulation and therapeutics.Signal transduction and targeted therapy · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Dual near-infrared II laser modulates the cellular redox state of T cells and augments the efficacy of cancer immunotherapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Eleanor I AgerEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Sergey V KozinEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Nathaniel D KirkpatrickEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Giorgio SeanoEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
David P KodackEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Vasileios AskoxylakisEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Yuhui HuangEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Shom GoelEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Matija SnuderlEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Alona MuzikanskyEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Dianne M FinkelsteinEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Daniel T DransfieldEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Laetitia DevyEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Yves BoucherEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD).
Dai FukumuraEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD). jain@steele.mgh.harvard.edu dai@steele.mgh.harvard.edu.
Rakesh K JainEdwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston MA (EIA, SVK, NDK, GS, DPK, VA, YH, SG, MS, YB, DF, RKJ); Department of Surgery (Austin Health), University of Melbourne, Studley Road Heidelberg, VIC, Australia (EIA); Novogen, Hornsby, NSW, Australia (EIA); Novartis Institutes for BioMedical Research, Cambridge, MA (NDK); Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Camperdown, NSW, Australia (SG); Department of Biostatistics, Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts (AM, DMF); Department of Pathology, NYU Langone Medical Center and Medical School, New York, NY (MS); Dyax Corp., Burlington, MA (DTD, LD); Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (SG); Tokai Pharmaceuticals, Inc., Cambridge, MA (DTD); Merck Serono S. A., Geneva, Switzerland (LD). jain@steele.mgh.harvard.edu dai@steele.mgh.harvard.edu.
Centenary Institute · AUDana-Farber Cancer Institute · USHarvard University · USMassachusetts General Hospital · USAustin Hospital · AUNYU Langone Health · US

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2016
$35.0M
TRD3: Percutaneous and Interstitial ImagingP41EB015903 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI Brett E Bouma · 2012 to 2026
$22.4M
Probing Tumor Microenvironment Using NanotechnologyR01CA126642 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2008 to 2012
$8.3M
NO in Tumor Angiogenesis,Microcirculation &Rad.TherapyR01CA096915 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2002 to 2012
$3.0M
Doppler Optical Frequency Domain Imaging InstrumentS10RR027070 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2010 to 2010
$260k
NCI NIH HHS P01 CA080124NCI NIH HHS P01-CA080124NCI NIH HHS P30-CA06516NCI NIH HHS R01-CA096915NCI NIH HHS R01-CA126642NCRR NIH HHS S10-RR027070NIBIB NIH HHS P41 EB015903
6 · The paper itself

Abstract

backgroundMatrix metalloproteinase (MMP) 14 may mediate tumor progression through vascular and immune-modulatory effects.

methodsOrthotopic murine breast tumors (4T1 and E0771 with high and low MMP14 expression, respectively; n = 5-10 per group) were treated with an anti-MMP14 inhibitory antibody (DX-2400), IgG control, fractionated radiation therapy, or their combination. We assessed primary tumor growth, transforming growth factor β (TGFβ) and inducible nitric oxide synthase (iNOS) expression, macrophage phenotype, and vascular parameters. A linear mixed model with repeated observations, with Mann-Whitney or analysis of variance with Bonferroni post hoc adjustment, was used to determine statistical significance. All statistical tests were two-sided.

resultsDX-2400 inhibited tumor growth compared with IgG control treatment, increased macrophage numbers, and shifted the macrophage phenotype towards antitumor M1-like. These effects were associated with a reduction in active TGFβ and SMAD2/3 signaling. DX-2400 also transiently increased iNOS expression and tumor perfusion, reduced tissue hypoxia (median % area: control, 20.2%, interquartile range (IQR) = 6.4%-38.9%; DX-2400: 1.2%, IQR = 0.2%-3.2%, P = .044), and synergistically enhanced radiation therapy (days to grow to 800mm(3): control, 12 days, IQR = 9-13 days; DX-2400 plus radiation, 29 days, IQR = 26-30 days, P < .001) in the 4T1 model. The selective iNOS inhibitor, 1400W, abolished the effects of DX-2400 on vessel perfusion and radiotherapy. On the other hand, DX-2400 was not capable of inducing iNOS expression or synergizing with radiation in E0771 tumors.

conclusionMMP14 blockade decreased immunosuppressive TGFβ, polarized macrophages to an antitumor phenotype, increased iNOS, and improved tumor perfusion, resulting in reduced primary tumor growth and enhanced response to radiation therapy, especially in high MMP14-expressing tumors.

Indexed as

AmidinesAnimalsAntibodies, MonoclonalAntineoplastic AgentsBenzylaminesBreast NeoplasmsCell Line, TumorDose Fractionation, RadiationEnzyme InhibitorsFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansImmunoglobulin GMacrophagesMammary Neoplasms, ExperimentalAmidinesAntibodies, MonoclonalAntineoplastic AgentsBenzylaminesEnzyme InhibitorsImmunoglobulin GMatrix Metalloproteinase 14MMP14 protein, humanN-(3-(aminomethyl)benzyl)acetamidineNitric Oxide Synthase Type IINOS2 protein, humanSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor beta

Identifiers

PMID25710962
PMCPMC4402365
OpenAlexW2096487280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.